Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatitis C virus kinetics.

E Herrmann1, A U Neumann, J M Schmidt

  • 1Department of Mathematics, Darmstadt University of Technology, Germany.

Antiviral Therapy
|September 6, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thyroid dose guidance in elective supraclavicular breast radiotherapy: a national survey of practice patterns in Switzerland.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026
Same author

The shifting shelf task: a new, non-verbal measure for attentional set shifting.

Proceedings. Biological sciences·2023
Same author

Heterotopia in Individuals with 22q11.2 Deletion Syndrome.

AJNR. American journal of neuroradiology·2021
Same author

Age-dependent gene expression of Calliphora vicina pupae (Diptera: Calliphoridae) at constant and fluctuating temperatures.

International journal of legal medicine·2021
Same author

Antiretroviral treatment outcomes among late HIV presenters initiating treatment with integrase inhibitors or protease inhibitors.

HIV medicine·2020
Same author

Oil supplementation with a special combination of n-3 and n-6 long-chain polyunsaturated fatty acids does not protect for exercise induced asthma: a double-blind placebo-controlled trial.

Lipids in health and disease·2020
Same journal

Safety and efficacy of deltoid intramuscular long-acting cabotegravir and rilpivirine, a case series.

Antiviral therapy·2026
Same journal

Factors associated with immunological non-response in HIV patients receiving antiretroviral therapy in Southeast Asia: A systematic review.

Antiviral therapy·2026
Same journal

Epidemiology and clinical management of cytomegalovirus infection in transplant recipients in Central and Eastern Europe - a physician survey.

Antiviral therapy·2026
Same journal

It's about time: The association between abacavir and cardiovascular disease.

Antiviral therapy·2026
Same journal

Combination antiviral and anti-CMV immunoglobulin therapy for CMV infection: A case-control study.

Antiviral therapy·2026
Same journal

Harnessing SuperNatural database to identify VP35 inhibitors as anti-Ebola drug candidates: A multistage <i>In silico</i> study.

Antiviral therapy·2025
See all related articles

Hepatitis C virus (HCV) treatment response can be predicted by analyzing viral load decline kinetics during early interferon-alpha therapy. This analysis helps optimize treatment and evaluate new drugs.

Area of Science:

  • Virology
  • Pharmacokinetics
  • Mathematical Modeling

Background:

  • Chronic hepatitis C virus (HCV) infection involves a dynamic balance of virus production and clearance.
  • Initiating antiviral treatment, such as interferon-alpha, leads to a decline in HCV viraemia.

Purpose of the Study:

  • To analyze the kinetics of viral load decline during early interferon-alpha therapy for chronic hepatitis C.
  • To determine if viral decay patterns can predict treatment response and inform therapeutic strategies.

Main Methods:

  • Kinetic analysis of viral load decline during the initial weeks of interferon-alpha therapy.
  • Mathematical modeling of viral dynamics to estimate viral production, clearance, and infected cell half-lives.
  • Evaluation of the impact of interferon-alpha monotherapy versus combination therapy with ribavirin.

Related Experiment Videos

Main Results:

  • HCV viral load exhibits a biphasic decline during interferon-alpha therapy: a rapid early phase followed by a slower exponential decay.
  • The rate of viral decline in the second phase is less dose-dependent but varies significantly among patients.
  • Infected cell death rate, influencing the second phase decline, predicts treatment response.
  • Combination therapy with ribavirin did not significantly alter initial viral decay but may reduce rebounds.

Conclusions:

  • Early kinetic analysis of viral decay during interferon-alpha treatment can predict end-of-therapy response.
  • Mathematical modeling provides insights into HCV viral dynamics, including infected cell turnover.
  • Findings support the use of frequent, high initial doses of interferon-alpha and suggest potential for optimizing therapy and evaluating new drugs.